Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study Article

ESI Most Cited Paper International Collaboration

cited authors

  • Harding, James J.; Fan, Jia; Oh, Do-Youn; Choi, Hye Jin; Kim, Jin Won; Chang, Heung-Moon; Bao, Lequn; Sun, Hui-Chuan; Macarulla, Teresa; Xie, Feng; Metges, Jean-Phillippe; Ying, Jie'er; Bridgewater, John; Lee, Myung-Ah; Tejani, Mohamedtaki A.; Chen, Emerson Y.; Kim, Dong Uk; Wasan, Harpreet; Ducreux, Michel; Bao, Yuanyuan; Boyken, Lisa; Ma, Jiafang; Garfin, Phillip; Pant, Shubham; HERIZON BTC 01 Study Grp

authors

Publication Date

  • July 1, 2023

webpage

published in

category

start page

  • 772

end page

  • 782

volume

  • 24

issue

  • 7